Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents

NCT01289847 is registered in ClinicalTrials.gov with Bio Products Laboratory as lead sponsor.

NCT NCT01289847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01289847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents
Lead sponsor
Bio Products Laboratory
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2011
Completion date
April 30, 2014
Enrollment
25 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

common variable immunodeficiency, hyper-igm syndrome, primary immune deficiency disorders, wiskott-aldrich syndrome, x-linked agammaglobulinemia